Abemaciclib

Abemaciclib（CAS 1231929-97-7）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.Abemaciclib is a unique cyclin-dependent kinase inhibitor that is used in combination with an antiestrogen in the treatment of postmenopausal women with metastatic breast cancer. Abemaciclib is associated with a moderate rate of serum aminotransferase elevations during therapy and has been linked to rare cases of clinically apparent liver injury.

同义词与商品名

Abemaciclib; 1231929-97-7; LY2835219; Verzenio; LY-2835219; Verzenios; 60UAB198HK; LY 2835219; LY2835210; LY-2835210; abemaciclibum; RefChem:58097; L01XE50; LY2385219; 806-670-8; LY2835219 free base

已收录的法规名录

GHS notification summary	20% (1 / 5)

GHS 危害分类

GHS notification summary	20% (1 / 5)
Reported hazard statements	H360 (60%), H373 (80%), H400 (80%), H410 (80%)

This chemical does not meet GHS hazard criteria for 20% (1 of 5) of reports.

H360 (60%): May damage fertility or the unborn child [Danger Reproductive toxicity]

公开数据库对它的描述

Abemaciclib · CAS 1231929-97-7 · C27H32F2N8. UNII 60UAB198HK.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。